List of Gocovri drug patents

Gocovri is owned by Adamas Pharma.

Gocovri contains Amantadine Hydrochloride.

Gocovri has a total of 18 drug patents out of which 0 drug patents have expired.

Gocovri was authorised for market use on 24 August, 2017.

Gocovri is available in capsule, extended release;oral dosage forms.

Gocovri can be used as treatment of dyskinesia and increasing on time without troublesome dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, treatment of dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, treatment of dyskinesia, decreasing off time, and increasing on time without troublesome dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, treatment of dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; treatment of dyskinesia and increasing on time without troublesome dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; decreasing off time in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, treatment of dyskinesia in patients with parkinson's disease receiving immediate release levodopa-based therapy, with or without concomitant dopaminergic medications, treatment of dyskinesia and decreasing off time in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

The generics of Gocovri are possible to be released after 23 August, 2038.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8889740 ADAMAS PHARMA Composition and method for treating neurological disease
Nov, 2025

(2 years from now)

US8895616 ADAMAS PHARMA Composition and method for treating neurological disease
Nov, 2025

(2 years from now)

US8796337 ADAMAS PHARMA Composition and method for treating neurological disease
Nov, 2025

(2 years from now)

US8895617 ADAMAS PHARMA Composition and method for treating neurological disease
Nov, 2025

(2 years from now)

US8895618 ADAMAS PHARMA Composition and method for treating neurological disease
Nov, 2025

(2 years from now)

US8895614 ADAMAS PHARMA Composition and method for treating neurological disease
Nov, 2025

(2 years from now)

US8895615 ADAMAS PHARMA Composition and method for treating neurological disease
Nov, 2025

(2 years from now)

US8389578 ADAMAS PHARMA Composition and method for treating neurological disease
Jan, 2028

(4 years from now)

US9877933 ADAMAS PHARMA Method of administering amantadine prior to a sleep period
Dec, 2030

(7 years from now)

US9867791 ADAMAS PHARMA Method of administering amantadine prior to a sleep period
Dec, 2030

(7 years from now)

US9867792 ADAMAS PHARMA Method of administering amantadine prior to a sleep period
Dec, 2030

(7 years from now)

US11197835 ADAMAS PHARMA Method of administering amantadine prior to a sleep period
Dec, 2030

(7 years from now)

US8741343 ADAMAS PHARMA Method of administering amantadine prior to a sleep period
Dec, 2030

(7 years from now)

US9867793 ADAMAS PHARMA Method of administering amantadine prior to a sleep period
Dec, 2030

(7 years from now)

US10646456 ADAMAS PHARMA Methods of administering amantadine
Jun, 2034

(11 years from now)

US10154971 ADAMAS PHARMA Methods of administering amantadine
Dec, 2034

(11 years from now)

US11065213 ADAMAS PHARMA Amantadine compositions and preparations thereof
Aug, 2038

(15 years from now)

US11077073 ADAMAS PHARMA Methods of using amantadine compositions
Aug, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 24, 2024

Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 August, 2017

Treatment: Treatment of dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; Treatment of dyskinesia in patients with parkinson's disease receiving immediate release levodopa-based therapy, with or without concomitant dopaminergic medications; Treatment of dyskinesia and increasing on time without troublesome dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; Treatment of dyskinesia, decreasing off time, and increasing on time without troublesome dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; Treatment of dyskinesia and decreasing off time in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; Decreasing off time in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of GOCOVRI before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic